RevitalVision says new trials show vision gains across eye diseases

By AI, Created 11:17 AM UTC, May 20, 2026, /AGP/ – RevitalVision announced new clinical evidence from six randomized controlled trials and a seven-year follow-up study showing its perceptual learning software improved vision across multiple eye conditions. The company says the results support broader use of brain-based vision training in routine eye care, especially for patients who have few treatment options left.

Why it matters: - RevitalVision is positioning perceptual learning as a practical add-on to standard eye care for patients whose vision remains limited after conventional treatment. - The clinical data point to gains in visual acuity, contrast sensitivity and binocular function across several ophthalmic conditions. - The company says the evidence supports integrating its software into routine clinical practice for patients and clinicians who are still dissatisfied with best-corrected vision.

What happened: - RevitalVision announced new clinical evidence on May 7, 2026, from Modiin, Israel. - The company said six randomized controlled trials completed in 2025 showed meaningful vision improvements across multiple eye conditions. - Three of those studies were published in peer-reviewed ophthalmology journals. - A seventh study showed long-term stability of visual gains in amblyopia over five years. - RevitalVision also pointed to sports-vision results from professional soccer players at Belgian Premier League club Standard Liège.

The details: - In the American Journal of Ophthalmology, patients with stable keratoconus who used RevitalVision improved by an average of 1.7 lines in best-corrected visual acuity, while the control group showed no improvement. - Nearly half of the keratoconus patients also improved in stereoacuity. - The same study reported significant gains in contrast sensitivity. - In the British Journal of Ophthalmology, patients ages 9 to 55 with infantile nystagmus improved distance visual acuity by 1.1 lines and near visual acuity by 2 lines. - In that nystagmus trial, 46% of patients reached vision levels sufficient for driving. - Also in that study, 76% of patients said they would recommend the treatment. - Patients in the control group who later crossed over to active treatment also improved substantially. - A follow-up study in the Latin American Journal of Ophthalmology found sustained benefits in amblyopia patients ages 8 to 40. - That study showed an average improvement of more than two lines in visual acuity, with results remaining stable over five years. - Three additional randomized controlled trials presented at ASCRS 2025 won Best Scientific Paper Awards in their sessions. - Those ASCRS studies showed significant improvement in patients with keratoconus. - Those studies also showed improvement in post-cataract surgery patients with multifocal intraocular lenses who had neuroadaptation difficulties. - In the Standard Liège group, visual acuity improved from 20/20 to 20/15. - The soccer players also showed significant improvements in contrast sensitivity. - RevitalVision said the software is the only FDA-cleared product for amblyopia in people age 9 and older. - The company said its training software is clinically proven across corneal and retinal diseases, post-cataract and laser refractive surgery, sports vision training and other visual impairments. - RevitalVision said the software provides real-time progress tracking and customizable routines. - The company has offices in the U.S. and Israel.

Between the lines: - The results reinforce a broader argument that adult vision can improve through neural adaptation, not only through lenses, surgery or medication. - The company is trying to move perceptual learning from a niche therapy into mainstream ophthalmology. - The strongest commercial opportunity appears to be in patients with persistent deficits after standard treatment, where unmet need is highest. - CEO Yair Yahav said the results provide evidence that the adult brain retains residual neuroplasticity that can be leveraged to improve visual performance. - Yahav compared the approach to prescribing physical therapy after surgery or injury.

What’s next: - RevitalVision is likely to use the new trial data to support broader clinical adoption and further physician education. - The company also appears to be building evidence for use cases beyond amblyopia, including keratoconus, nystagmus, post-surgical neuroadaptation and sports performance. - The next step for the market is whether eye-care providers treat perceptual learning as a routine option rather than an experimental add-on.

The bottom line: - RevitalVision now has a stronger case that software-based perceptual training can produce measurable and durable vision gains across multiple eye conditions.